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Abstract
We attempted to determine the usefulness of body surface mapping (BSM) for differentiat-
ing patients with Brugada syndrome (BS) from patients with asymptomatic Brugada syndrome
(ABS). Electrocardiograms (ECG) and BSM were recorded in 7 patients with BS and 35 patients
with ABS. Following the administration of Ic antiarrhythmic drugs, BSM was recorded in 5 pa-
tients with BS and 16 patients with ABS. The maximum amplitudes at J0, J20, J40 and J60 were
compared between the 2 groups, as were 3-dimensional maps. The maximum amplitudes at J0,
J20 and J60 under control conditions were larger in patients with BS than in patients with ABS (P
< 0.05). A three-dimensional map of the ST segments under control conditions in patients with BS
showed a higher peak of ST elevation in the median precordium compared to that for patients with
ABS. Increases in ST elevation at J20, J40 and J60 following drug administration were greater in
patients with BS than in patients with ABS (P < 0.05). Evaluation of the change in amplitude of
the ST segment at E5 caused by Ic drug administration was also useful for differentiating between
the 2 groups. In conclusion, BSM was useful for differentiating patients with BS from those with
ABS.
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We attempted to determine the usefulness of body surface mapping (BSM) for diﬀerentiating patients with Brugada syndrome(BS)from patients with asymptomatic Brugada syndrome(ABS).
Electrocardiograms(ECG)and BSM were recorded in 7 patients with BS and 35 patients with ABS.
Following the administration of Ic antiarrhythmic drugs, BSM was recorded in 5 patients with BS and 16 patients with ABS. The maximum amplitudes at J0, J20, J40 and J60 were compared between the 2 groups, as were 3-dimensional maps. The maximum amplitudes at J0, J20 and J60 under control conditions were larger in patients with BS than in patients with ABS ( ＜0.05). A three-dimensional map of the ST segments under control conditions in patients with BS showed a higher peak of ST elevation in the median precordium compared to that for patients with ABS.
Increases in ST elevation at J20, J40 and J60 following drug administration were greater in patients with BS than in patients with ABS ( ＜0.05). Evaluation of the change in amplitude of the ST segment at E5 caused by Ic drug administration was also useful for diﬀerentiating between the 2 groups. In conclusion, BSM was useful for diﬀerentiating patients with BS from those with ABS.
Key words:body surface map, Brugada syndrome, asymptomatic Brugada syndrome, Ic antiarrhythmic drugs
 
I n 1992, Pedro Brugada and Joseph Brugada described eight cases of sudden cardiac death due to ventricular ﬁbrillation (VF)without structural heart disease［1］. Electrocardiograms(ECG)of those patients were characterized by right bundle branch block with ST segment elevation in the right precordial leads(V1-V2).
Treatment with antiarrhythmic drugs is not eﬀective for preventing cardiac events;only an implantable cardioverter-deﬁbrillator(ICD)is eﬀective for preventing
 
sudden death. However, the recommendation of ICD implantation for patients showing Brugada-type ECG characteristics but with no history of VF or syncope
(asymptomatic Brugada syndrome) is controversial.
Brugada and Brugada recently recommended ICD im-
plantation for asymptomatic patients who had a spontane-
ously abnormal ECG, and in whom ventricular arrhyth-
mias were inducible［2］. Priori et al. reported that information on the history of asymptomatic patients was important for quantifying the risk for sudden cardiac death, and for deciding whether an ICD should be used
［3］. We reported that asymptomatic Brugada syndrome without an obvious family history of sudden cardiac death
 
Received May 28,2003;accepted October 8,2003.
?Corresponding author.Phone:＋81-86-235-7351;Fax:＋81-86-235-7353 E-mail:kenichi＠cc.okayama-u.ac.jp(K.Hisamatsu)
http://www.lib.okayama-u.ac.jp/www/acta/
Acta Med. Okayama, 2004 Vol. 58, No. 1, pp. 29 -35
 
Original Article
 
Copyright?ｃ2004 by Okayama University Medical School.
1
Hisamatsu et al.: Usefulness of body surface mapping to differentiate patients
Produced by The Berkeley Electronic Press, 2004
was a relatively benign disease during a mean follow-up period of 42.5±21.6 months［4］. Thus, we believe that it is important to diﬀerentiate patients with Brugada syndrome from those with asymptomatic Brugada syn-
drome.
Recent studies have shown that body surface mapping
(BSM)is useful for evaluating the characteristics of ST elevation in symptomatic patients with Brugada syndrome
［5, 6］. The present study was therefore carried out to determine whether patients with Brugada syndrome and those with asymptomatic Brugada syndrome could be discriminated on the basis of ST elevation characteristics using body surface mapping (BSM).
Materials and Methods
 
Brugada-type ECG showed the typical electrocardiographic“Brugada sign,”which was deﬁned previously［4］. We deﬁned patients with asymptomatic Brugada syndrome as patients with Brugada-type ECG,
and with no history of spontaneous VF or syncope before the examinations, regardless of a family history of sudden death. The subjects were 42 patients with Brugada-type ECG(including 7 patients with Brugada syndrome and 35 patients with asymptomatic Brugada syndrome). The clinical and electrocardiographic characteristics of the subjects are summarized in Table 1. The ages of the patients in the 2 groups were not signiﬁcantly diﬀerent
(48±7 vs. 47±8 years old). Four of the 7 patients with Brugada syndrome and 1 of the 35 patients with asymptomatic Brugada syndrome had family histories of sudden death. However, this single asymptomatic patient’s family history was not an obvious family history of sudden cardiac death due to Brugada syndrome and VF. No statistically signiﬁcant diﬀerences were observed between the 2 groups with regards to each parameter.
The results of physical examination, chest X-ray, exer-
cise ECG and echocardiogram showed no evidence of structural heart disease in any of the patients.
The ECG and BSM recording were performed in the 7 patients with Brugada syndrome and in the 35 patients with asymptomatic Brugada syndrome.
BSM was performed using a VCM-3000 (Fukuda Denshi Co., Tokyo, Japan). During sinus rhythm,
unipolar electrocardiograms were recorded simultaneously from 87 lead points. Of these, 59 leads were located on the anterior region of the chest(A-I), and 28 were leads
 
located on the back(J-M)(Fig. 1). Row 6 coincided with the level of the parasternal second intercostal space. Row 4 coincided with the mid-clavicular ﬁfth intercostal space.
Row 5 was between rows 6 and 4, and rows 7, 3, 2 and 1 were located vertically at equal intervals. Columns A and I were located on the right and left mid-axillary lines,
respectively. Column E was located on the midsternal line. Columns C and G corresponded to the right and left mid-clavicular lines, respectively.
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Table 1  Clinical and electrocardiographic characteristics
 
Patients with Brugada syndrome
 
Patients with asymptomaitc Brugada syndrome  
P
 
Total, n  7  35 Age, y  48±7  47±8  NS VF/syncope, n  7  0 Family history of sudden death, n  4  1 
ECG PR interval, msec  179.2±25.7  164±20.6  NS QTc, msec  429.7±46.3  412.6±42.8  NS SAECG f-QRS, msec  120.0±10.8  116.8±9.2  NS LAS40, msec  47.7±12.7  40.7±10.7  NS RMS40, μV  12.2±7.3  18.2±9.5  NS
 
ECG, electrocardiograms;f-QRS, ﬁltered QRS duration;LAS40,
duration of low-amplitude-signals of＜40μV;QTc, corrected QT interval;RMS40, root-mean-square voltage of the terminal 40 msec of the ﬁltered QRS complex;SAECG, signal-averaged electrocardio-
grams;VF, ventricular ﬁbrillation.
Fig.1  Eighty-seven lead points. During sinus rhythm, unipolar electrocardiograms were recorded simultaneously from the 87 lead points. The location of D-G, 4-7, shown as an open square in this ﬁgure, indicates the median precordium. Crosses indicate the stan dard positions of precordial leads V1 to V6.
-
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The J point was determined by the J point of H4. The amplitudes of the ST segment 20 msec(J20), 40 msec
(J40)and 60 msec(J60)after the J point were measured in the 87 leads in order to construct potential maps of each point.
To visualize the spatial distribution of ST elevation, we constructed a 3-dimensional map (3D map) using potential mapping data.
The drug challenge test was performed while the patient was being continuously monitored with a deﬁbrillator in the coronary care unit, because the administration of Ic antiarrhythmic drugs to patients with Brugada syndrome can cause serious and life-threatening arrhythmias, such as VF.
Following the administration of pilsicainide, BSM was performed in 5 patients with Brugada syndrome and in 16 patients with asymptomatic Brugada syndrome. Pil-
sicainide (1 mg/kg), which is a pure sodium channel blocker and has a relatively short half-life compared to other Ic agents, was infused intravenously over a period of 10 min. BSM was performed at baseline and at 5 min after the infusion of the drug.
Data are expressed as means±SD. Student’s t-test was used to analyze diﬀerences between the patients with Brugada syndrome
 
and those with asymptomatic Brugada syndrome. P＜
0.05 was considered statistically signiﬁcant. All calcula-
tions were done using StatView-J 5.0(SAS Institute Inc.,
Cary, NC, USA).
Results
 
The maximum amplitudes at J0, J20 and J60 were larger in patients with Brugada syndrome than in those with asymptomatic Brugada syndrome(2.17±1.20 vs.1.26±
0.98 mV, P＜0.05;2.08±1.20 vs. 1.03±0.79 mV,
P＜0.05;1.67±0.76 vs. 1.07±0.64 mV, P＜0.05,
respectively). No statistically signiﬁcant diﬀerences were observed between the 2 groups with regards to the maximum amplitude at J40.
The maximum amplitudes at J0, J20, J40 and J60 in the Brugada syndrome group were located at the high median precordium(E-F, 5-6)in 7 of the 7 patients(100
), 6 of the 7 patients(85.7 ), 5 of the 7 patients(71.4
)and 5 of the 7 patients(71.4 ), respectively(Fig. 2).
In the asymptomatic Brugada syndrome group, the maximum amplitudes at the same J points were located at the high median precordium in 31 of the 35 patients(88.6
), 17 of the 35 patients(48.6 ), 10 of the 35 patients
(28.6 )and 7 of the 35 patients (20 ), respectively.
It has been reported that 16-lead electrograms (D-G,
ST Segment Elevation of Brugada Syndrome February 2004
 
Fig.2  Locations of maximum ST elevation on body surface maps(D-G, 3-7)in 7 patients with Brugada syndrome(solid circles)and in 35 patients with asymptomatic Brugada syndrome(open circles)under control conditions. Figs.a-d show the locations at J0, J20, J40 and J60,
respectively.
31
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4-7)can be expected to reﬂect the potentials of the right ventricular outﬂow tract (RVOT)［5］. Our results showed that the maximum amplitude was located in a narrower region of the RVOT in patients with Brugada syndrome than in patients with asymptomatic Brugada syndrome.
The 3D maps showed that the Brugada syndrome group had a higher peak at the median precordium, especially at E5, than did the asymptomatic Brugada syndrome group (Fig. 3).
Fig. 3B shows that the blue area at the top of the 3D map was coincident with the right ventricular outﬂow tract
(RVOT)area.
Statistically signiﬁcant diﬀerences between the 2 groups were observed in the degree of amplitude increase(post-pre/pre)caused by drug administration at J20, J40 and J60 (1.93±1.20 vs.0.63±1.02, 2.00±
1.00 vs.0.56±0.89, 2.11±0.89 vs.0.66±0.99, respec-
tively).
Following the drug administration, ST elevation in-
creased in extent and magnitude in both patient groups.
However, the increased extent and magnitude were greater in symptomatic than asymptomatic Brugada syn-
drome, resulting in the higher and sharper peak on the 3D map, located at E5, for the symptomatic Brugada syn-
drome(Fig. 4). Fig. 4D shows that the blue area at the
 
Fig.4  Three-dimensional maps of the ST segment at J20 before administration of an Ic antiarrhythmic drug(A, B)and after administration
(C, D). The left traces(A, C)are data from patients with asymptomatic Brugada syndrome(n＝16), and the right traces(B, D)are data from patients with Brugada syndrome(n＝5). The post-administration 3D maps show that patients with Brugada syndrome have a higher peak at the median precordium than do patients with asymptomatic Brugada syndrome.
Fig. 3  Three-dimensional maps of the ST segment at J20. To visualize the spatial distribution of the ST elevation, a 3D map was constructed using potential mapping data. The Z-axis indicates the amplitude of the ST level, and the X and Y-axes indicate the record ing sites. These 3D maps were produced by grouping data of potential mapping from the 2 groups (asymptomatic Brugada syn drome patients, n＝35;Brugada syndrome patients, n＝7).
Patients with Brugada syndrome (B) have a higher peak at the median precordium than do patients with asymptomatic Brugada syndrome(A).
-
-
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top of the 3D map was coincident with the RVOT area.
From the results described above, we applied the following criteria for separating patients with Brugada syndrome from patients with asymptomatic Brugada syndrome:(1)
patients with the coved-type ECG at E5 after Ic drug administration, and(2)patients with an amplitude at E5＞
1.5 mV after Ic drug administration, or(3)a degree of amplitude increase(post-pre/pre)at E5 of＞2.0. These criteria had a sensitivity of 100 , a speciﬁcity of 69 ,
a positive predictive value of 50 , and a negative predictive value of 100 (Table 2).
During a mean follow-up period of 47±20 months,
an ICD was implanted due to VF in one of the 5 patients with asymptomatic Brugada syndrome who fully fulﬁlled these criteria. However, one asymptomatic Brugada syndrome patient with a family history of sudden death of unknown cause did not fulﬁll these criteria and had no syncopal episode due to VF during the follow-up period.
Discussion
 
The characteristics of patients with Brugada syndrome are ST elevation in the right precordial leads(V1-V2)of the ECG and a past history of sudden cardiac death due to VF without structural heart disease. Treatment with antiarrhythmic drugs is not eﬀective in preventing the occurrence of cardiac events in patients with Brugada syndrome. Thus, ICD implantation is usually used to treat patients with Brugada syndrome.
We have often observed Brugada syndrome-type characteristics in the ECGs of patients who have no Brugada syndrome symptoms and are considered to healthy(Figs. 5A-B). Thus, it is necessary to identify those patients who have latent Brugada syndrome, and it
 
is important to predict whether cardiac events will occur in the future in patients with asymptomatic Brugada syndrome.
Recently, a molecular abnormality in the cardiac sodium channel gene, SCN5A, was reported to be the genetic basis of Brugada syndrome［7］. Following the publication of that report, relationships have been report-
ed between Brugada syndrome and mutations of SCN5A
［8-11］. Priori et al.described appropriate management strategies for patients showing Brugada-type ECGs based on the concept that this syndrome was a novel cardiac ion channel disease［3］.
However, it is diﬃcult to perform gene analysis in all patients showing Brugada-type ECGs. Thus, we attempted to diﬀerentiate the characteristics of ST eleva-
tion in patients with Brugada syndrome from those in
 
Fig.5  Twelve-lead ECG obtained under control conditions(A, B)
and from 16-lead electrocardiograms (D-G, 4-7)selected from the 87-lead ECG(C, D). The left traces(A, C)are data from a patient with asymptomatic Brugada, and the right traces (B, D)are data from a patient with Brugada syndrome. Arrows indicate the remark able diﬀerences in ST segment elevation in a patient with Brugada syndrome.
-
Table 2  Comparison of results obtained on the basis of the new criteria
 
Results  Patients with Brugada syndrome
 
Patients with asymptomatic Brugada syndrome  
Number
 
Positive  5  5  10 Negative  0  11  11
 
Number  5  16  21
 
33 ST Segment Elevation ofBrugada Syndrome February 2004
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patients with asymptomatic Brugada syndrome by BSM before and after pharmacological challenge tests with pilsicainide.
BSM,which is a noninvasive and simple method,was superior to 12-lead ECG in demonstrating spatial distribu-
tion (Figs. 5C-D). BSM could therefore be a useful method for diagnosing Brugada syndrome. Di Diego et al.reported the possible mechanisms of the appearance of ST segment elevation only in the right precordial leads in patients with Brugada syndrome［12］. Shimizu et al.
compared their ﬁndings in patients with Brugada syn-
drome with those in healthy subjects, and demonstrated using BSM that the location of the maximal amplitude in Brugada syndrome patients was in an area of the RVOT
(D-G, 4-7)［5］. In the present study, we obtained similar results in comparison with patients with asymptomatic Brugada syndrome. Our results also showed that the maximum amplitude was located in a narrower region of the median precordium(E-F, 5-6)in patients with Brugada syndrome in comparison with Shimizu et al’s recent results.
The results of challenge tests using Ic antiarrhythmic drugs have been reported to be helpful in the diagnosis of Brugada syndrome［13-17］. Our results showed that the administration of Ic antiarrhythmic drugs made it easier to diﬀerentiate patients with Brugada syndrome from those with asymptomatic Brugada syndrome (Figs. 6A-B).
Even in cases in which it was diﬃcult to diﬀerentiate the 2 groups using BSM under control conditions,
diﬀerentiation by BSM was possible following the admin-
istration of Ic antiarrhythmic drugs (Figs. 6C-D).
We reported that the change in amplitude of the ST segment at lead V2, not lead V1, after drug administra-
tion was useful for diﬀerentiating asymptomatic Brugada syndrome patients with inducible VF from asymptomatic Brugada syndrome patients without inducible VF by programmed electrical stimulation［16］. E5 is located between V1 and V2, and above V1 and V2. E5 is also expected to reﬂect the potentials of the nearer RVOT.
Thus, since the peak amplitude of ST elevation in symptomatic Brugada syndrome was located in a quite narrow area of the anterior chest observed in this study,
the amplitude at E5 was more sensitive than that at V2 for evaluating abnormal electrical activity in RVOT. This higher sensitivity allowed us to separate the patients with symptomatic Brugada syndrome from those with asymptomatic Brugada syndrome using the criteria de-
scribed above.
It is well known that the ECG in Brugada syndrome patients diﬀers from day to day, and that the autonomic nervous system aﬀects the modulation of ST segment elevation in Brugada syndrome patients［18-20］. How-
ever, each examination was performed only once in each patient. The patients in this study were also examined as a group, not individually. Thus, based only on our results, it is not possible to determine whether only BSM provides suﬃcient information for predicting the occur-
rence of future cardiac events in patients with asymptomatic Brugada syndrome. Follow-up and investi-
gation using combinations of BSM with other examina-
Fig.6  Twelve-lead ECG (A, B)and 16-lead electrocardiograms after administration of an Ic antiarrhythmic drug (D-G, 4-7)(C, D).
The left traces (A, C)are data from a patient with asymptomatic Brugada and the right traces (B, D)are data from a patient with Brugada syndrome. Administration of an Ic antiarrhythmic drug made it easier to diﬀerentiate a patient with Brugada syndrome from one with asymptomatic Brugada syndrome. Arrows indicate the remark able changes in ST segment elevation after the administration of an Ic antiarrhythmic drug in a patient with Brugada syndrome.
-
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tions are needed in order to further evaluate the re-
producibility of these ﬁndings and the individual outcomes.
However, it is possible that these methods might provide improved means of diﬀerentiating symptomatic and asymptomatic Brugada patients noninvasively.
In conclusion, BSM was useful for diﬀerentiating patients with Brugada syndrome from those with asymptomatic Brugada syndrome. The results of this study suggest that patients with Brugada syndrome had a higher elevation of the ST segment at the median precor-
dium than patients with asymptomatic Brugada syndrome,
and that diﬀerentiation of patients with Brugada syndrome from those with asymptomatic Brugada syndrome was easier if an Ic antiarrhythmic drug was administered.
Evaluation of the amplitude of the ST segment at E5 and evaluation of the change in amplitude of the ST segment at E5 caused by Ic drug administration were also useful for diﬀerentiating  symptomatic patients  from asymptomatic Brugada syndrome patients.
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